HeartWare's (HTWR) +15.5% premarket on news the company's implantable pump for heart-transplant...


HeartWare's (HTWR) +15.5% premarket on news the company's implantable pump for heart-transplant candidates wins the backing of an FDA advisory panel. If HTWR's Ventricular Assist System also is approved for patients who aren’t eligible for a transplant, the company could split the U.S. market with Thoratec’s (THOR) HeartMate device by 2015, analysts say.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs